242 related articles for article (PubMed ID: 32446746)
1. The Hippo Pathway as a Driver of Select Human Cancers.
Kulkarni A; Chang MT; Vissers JHA; Dey A; Harvey KF
Trends Cancer; 2020 Sep; 6(9):781-796. PubMed ID: 32446746
[TBL] [Abstract][Full Text] [Related]
2. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.
Sebio A; Lenz HJ
Clin Cancer Res; 2015 Nov; 21(22):5002-7. PubMed ID: 26384319
[TBL] [Abstract][Full Text] [Related]
4. Hippo pathway: Regulation, deregulation and potential therapeutic targets in cancer.
Mohajan S; Jaiswal PK; Vatanmakarian M; Yousefi H; Sankaralingam S; Alahari SK; Koul S; Koul HK
Cancer Lett; 2021 Jun; 507():112-123. PubMed ID: 33737002
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitination‑deubiquitination in the Hippo signaling pathway (Review).
Liu Y; Deng J
Oncol Rep; 2019 Mar; 41(3):1455-1475. PubMed ID: 30628704
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
[TBL] [Abstract][Full Text] [Related]
7. Genetic Alterations of TRAF Proteins in Human Cancers.
Zhu S; Jin J; Gokhale S; Lu AM; Shan H; Feng J; Xie P
Front Immunol; 2018; 9():2111. PubMed ID: 30294322
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
9. Cell Competition Spurs Selection of Aggressive Cancer Cells.
Parker T; Madan E; Gupta K; Moreno E; Gogna R
Trends Cancer; 2020 Sep; 6(9):732-736. PubMed ID: 32327348
[TBL] [Abstract][Full Text] [Related]
10. Filling out the Hippo pathway.
Saucedo LJ; Edgar BA
Nat Rev Mol Cell Biol; 2007 Aug; 8(8):613-21. PubMed ID: 17622252
[TBL] [Abstract][Full Text] [Related]
11. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
12. New insights into the core Hippo signaling and biological macromolecules interactions in the biology of solid tumors.
Mohammadi S; Arefnezhad R; Danaii S; Yousefi M
Biofactors; 2020 Jul; 46(4):514-530. PubMed ID: 32445262
[TBL] [Abstract][Full Text] [Related]
13. Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities.
Calses PC; Crawford JJ; Lill JR; Dey A
Trends Cancer; 2019 May; 5(5):297-307. PubMed ID: 31174842
[TBL] [Abstract][Full Text] [Related]
14. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
15. SGK1, autophagy and cancer: an overview.
Ghani MJ
Mol Biol Rep; 2022 Jan; 49(1):675-685. PubMed ID: 34669124
[TBL] [Abstract][Full Text] [Related]
16. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
[TBL] [Abstract][Full Text] [Related]
17. Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer.
Kim SH; Jin H; Meng RY; Kim DY; Liu YC; Chai OH; Park BH; Kim SM
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547587
[TBL] [Abstract][Full Text] [Related]
18. The Hippo pathway in chemotherapeutic drug resistance.
Zhao Y; Yang X
Int J Cancer; 2015 Dec; 137(12):2767-73. PubMed ID: 25348697
[TBL] [Abstract][Full Text] [Related]
19. Regulatory role of microRNAs in cancer through Hippo signaling pathway.
Astamal RV; Maghoul A; Taefehshokr S; Bagheri T; Mikaeili E; Derakhshani A; Delashoub M; Taefehshokr N; Isazadeh A; Hajazimian S; Tran A; Baradaran B
Pathol Res Pract; 2020 Dec; 216(12):153241. PubMed ID: 33065484
[TBL] [Abstract][Full Text] [Related]
20. The posttranslational modifications of Hippo-YAP pathway in cancer.
Yan F; Qian M; He Q; Zhu H; Yang B
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129397. PubMed ID: 31306710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
